Actualización terapéutica en la hepatitis C / Therapeutic update in hepatitis C
Rev. esp. quimioter
; 28(supl.1): 48-51, sept. 2015.
Article
in Spanish
| IBECS
| ID: ibc-140931
Responsible library:
ES1.1
Localization: BNCS
RESUMEN
La infección por el virus de hepatitis C es un problema de salud que afecta a 130-170 millones de personas en todo el mundo. Aproximadamente un 10-30% de pacientes con hepatitis crónica C progresarán a cirrosis en 20-30 años. El desarrollo de nuevos agentes antivirales de acción directa ha cambiado el manejo de la enfermedad, permitiendo el tratamiento libre de Interferón con eficacia superior a los regímenes terapéuticos previos y mínimos efectos adversos, incluso en algunos subgrupos previamente considerados difíciles de curar como los pacientes cirróticos (AU)
ABSTRACT
Hepatitis C virus infection is a major health burden affecting 130-170 million people worldwide. Approximately 10-30% of those with chronic hepatitis C will progress to cirrhosis over 20-30 years. The development of new direct-acting antivirals has changed the management of the disease, allowing efficacious Interferon-free therapies superior to prior treatment regimens with minimal side effects, even in some subgroups previously thought to be difficult to cure such as cirrhotic patients (AU)
Full text:
Available
Collection:
National databases
/
Spain
Health context:
SDG3 - Health and Well-Being
Health problem:
Target 3.3: End transmission of communicable diseases
Database:
IBECS
Main subject:
Antiviral Agents
/
Interferons
/
Hepatitis C
/
Combined Modality Therapy
/
Liver Cirrhosis
Type of study:
Diagnostic study
Limits:
Female
/
Humans
/
Male
Language:
Spanish
Journal:
Rev. esp. quimioter
Year:
2015
Document type:
Article
Institution/Affiliation country:
Hospital Clínico San Carlos/España